Page 54 - Let them speak Towards a patient reported outcome measure set for
P. 54
Chapter 2
65. Gaasterland CMW, Van Der Weide MCJ, Roes KCB, et al. Goal attainment scaling as an
outcome measure in rare disease trials: a conceptual proposal for validation. BMC Med Res
Methodol 2019; 19: 227.
66. Müller AR, Zinkstok JR, Rommelse NNJ, et al. Methylphenidate for attention-deficit/
hyperactivity disorder in patients with Smith–Magenis syndrome: protocol for a series of N-of-
1 trials. Orphanet J Rare Dis 2021; 16: 380.
67. Gaasterland CMW, Jansen-van der Weide MC, Vroom E, et al. The POWER-tool:
recommendations for involving patient representatives in choosing relevant outcome
measures during rare disease clinical trial design. Health Policy (New York). 2018; 122: 1287–
1294.
68. Crossnohere NL, Brundage M, Calvert MJ, et al. International guidance on the selection of
patient-reported outcome measures in clinical trials: a review. Qual Life Res 2021; 30: 21–40.
69. Pogrow S. How Effect size (practical significance) misleads clinical practice: the case for
switching to practical benefit to assess applied research findings. Am Stat 2019; 73(Suppl.
1): 223–234.
70. Morel T and Cano SJ. Measuring what matters to rare disease patients – Reflections on the
work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet J Rare Dis
2017;12: 171.
71. Terwee CB, Prinsen CAC, Chiarotto A, et al. COSMIN methodology for evaluating the content
validity of patient-reported outcome measures: a Delphi study. Qual Life Res 2018; 27: 1159–
1170.
72. Matts ST, Webber CM, Bocell FD, et al. Inclusion of patient-reported outcome instruments in
US FDA medical device marketing authorizations. J Patient-Rep Outcomes 2022; 6: 38.
73. US Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures
Use in Medical Product Development to Support Labeling Claims. Clinical/Medical Federal
Register, 2009.
74. Calvert M, King M, Mercieca-Bebber R, et al. SPIRIT-PRO Extension explanation and elaboration:
guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. BMJ Open
2021; 11: e045105.
52
